Vaxart, Inc. (OTCPK: VXRT)
Health Care · Biotechnology · US
$0.52
-5.24% today · +45.8% 1Y
Vaxart, Inc. (OTCPK: VXRT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $125.06M and employs 65 people.
Over the last twelve months the share price has gained 45.8%, trading between 0.31 and 0.84.
Tweenvest scores Vaxart, Inc. across four factors: quality 33/100, value 55/100, growth 100/100. Its strongest factor is growth.
VXRT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $125.06M
- Revenue (TTM)
- $243.06M
- P/E
- 3.18
- EPS
- 0.16
- Dividend yield
- —
- Beta (5Y)
- 1.07
- 52-week high
- $0.84
- 52-week low
- $0.31
- Avg volume (3M)
- —
- Shares outstanding
- 242.84M
- Employees
- 65
- Next earnings
- —
About Vaxart, Inc.
Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
- ISIN
- US92243A2006
- Listed since
- Dec 11, 1981
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.